clinical trial · NCT01678872
A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
Oxford BioMedica·phase1·active not recruiting·n = 18
Age-Related Macular DegenerationRetinoStat
brief summary
The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.
started
Aug 1, 2012
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
Jan 14, 2026
official title
A Long Term Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol